That covers roughly two and a half weeks of your initial escalation phase
As insulin resistance worsens, the pancreas works increasingly hard to maintain glucose control
Appetite remains suppressed, but without the accompanying gastrointestinal distress that made eating difficult during month 2
For this drug, the ongoing SOUL trial has shown promising preliminary results, indicating a 14% reduction in the risk of MACE (84)
Key findings at the highest dose (12mg weekly): Up to 24% mean body weight reduction over 48 weeks Significant reductions in fasting glucose and insulin resistance markers Meaningful reductions in liver fat content, relevant for participants with metabolic-associated fatty liver disease Once-weekly subcutaneous dosing was generally well-tolerated For context, semaglutide at its approved dose achieves approximately 1517% body weight reduction over 68 weeks
For Canadians exploring research peptides, understanding this mechanism helps explain why the 3-month results are so compelling
